Impulse Control Problems Linked to Antipsychotic, FDA WarnsImpulse Control Problems Linked to Antipsychotic, FDA Warns
The FDA is warning of impulse control problems associated with the atypical antipsychotic aripiprazole. News Alerts (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - May 3, 2016 Category: Psychiatry Tags: Psychiatry News Alert Source Type: news

FDA Drug Safety Communication: FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada)
[05-03-2016] The U.S. Food and Drug Administration (FDA) is warning that compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported with the use of the antipsychotic drug aripiprazole (Abilify, Abilify Maintena, Aristada, and generics). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 3, 2016 Category: Drugs & Pharmacology Source Type: news

MassDevice.com +5 | The top 5 medtech stories for April 27, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. FDA wants more from Proteus, Otsuka on ‘smart pill’ Otsuka Pharmaceutical and Proteus Digital Health said today that the FDA issued a complete response letter requesting more information from the companies for the c...
Source: Mass Device - April 27, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

FDA declines to approve Proteus-Otsuka sensor-equipped pill, asks for more tests
The FDA declined to approve what would have been the first mass market drug to incorporate Proteus Digital Health's ingestible sensor. The drug, a collaboration between Proteus and Otsuka Pharmaceuticals, combines the Proteus system with the antipsychotic pharmaceutical Abilify. (Source: mobihealthnews)
Source: mobihealthnews - April 27, 2016 Category: Information Technology Source Type: news

FDA wants more from Proteus, Otsuka on ‘smart pill’
Otsuka Pharmaceutical (TYO:4578) and Proteus Digital Health  said today that the FDA issued a complete response letter requesting more information from the companies for the combination of the Proteus “smart pill” and Otsuka’s Abilify anti-depressant drug. The Proteus pill is designed to signal a wearable patch after it reaches the stomach, recording and time-stamping data from the pill and other patient metrics. The data can be relayed via Bluetooth to mobile devices and, with consent, to healthcare providers. The federal watchdog is requesting new data from the companies, including inform...
Source: Mass Device - April 27, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Drug-Device Combinations Food & Drug Administration (FDA) Otsuka Pharmaceutical Proteus Digital Health Source Type: news

Drug and behavioural therapy are both effective for tics in people with Tourette syndrome
There are effective drug and behavioural treatments for tics in children and young people with Tourette syndrome. Although most of the studies included in this review were small with risk of , the effects found were moderate to large and likely to be clinically meaningful. This NIHR funded and qualitative study found that habit reversal therapy, where people with Tourette's are taught to replace their tic with a less noticeable alternative, was effective. The drugs with the best balance of benefits and harms – risperidone, clonidine and aripiprazole – are those most commonly used in the UK. (Source: Current Awa...
Source: Current Awareness Service for Health (CASH) - April 7, 2016 Category: Consumer Health News Source Type: news

Facts You Should Know When Taking Abilify for...
Read about the use of Abilify for bipolar disorder and other health conditions, as well as information on its side effects and two black box warnings. (Source: About.com Bipolar Disorder)
Source: About.com Bipolar Disorder - March 29, 2016 Category: Psychiatry Authors: bipolar.guide at about.com Tags: health Source Type: news

Aripiprazole versus chlorpromazine for people with schizophrenia and schizophrenia-like psychoses
The objectives are as follows: To review the effects of aripiprazole compared with chlorpromazine for people with schizophrenia and schizophrenia-like psychoses. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 17, 2016 Category: Consumer Health News Source Type: news

Aripiprazole versus haloperidol for people with schizophrenia and schizophrenia-like psychoses
The objectives are as follows: To review the effects of aripiprazole compared with haloperidol for people with schizophrenia and schizophrenia-like psychoses. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 17, 2016 Category: Consumer Health News Source Type: news

Aripiprozale versus haloperidol for people with schizophrenia and schizophrenia-like psychoses
The objectives are as follows: To review the effects of aripiprazole compared with haloperidol for people with schizophrenia and schizophrenia-like psychoses (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 17, 2016 Category: Consumer Health News Source Type: news

Aripiprazole versus perphenazine for people with schizophrenia and schizophrenia-like psychoses
The objectives are as follows: To review the effects of aripiprazole compared with perphenazine for people with schizophrenia. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 17, 2016 Category: Consumer Health News Source Type: news

Aripiprazole versus sulpiride for people with schizophrenia and schizophrenia-like psychoses
The objectives are as follows: To review the effects of aripiprazole compared with sulpiride for people with schizophrenia and schizophrenia-like psychoses. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 17, 2016 Category: Consumer Health News Source Type: news

Common Test May Aid Personalized Depression TreatmentCommon Test May Aid Personalized Depression Treatment
Preserved set-shifting capacity may mark a subgroup of older patients with resistant depression who may benefit from aripiprazole augmentation. Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - March 10, 2016 Category: Psychiatry Tags: Psychiatry News Source Type: news

Risperidone, aripiprazole treat irritability in children with ASD
Risperidone and aripiprazole, followed by N-acetylcysteine, appear most effective in treating irritability and aggression in youth with autism spectrum disorders (ASD), according to a systematic... (Source: Pediatric News)
Source: Pediatric News - March 2, 2016 Category: Journals (General) Source Type: news

Risperidone, aripiprazole treat irritability in children with ASD
Risperidone and aripiprazole, followed by N-acetylcysteine, appear most effective in treating irritability and aggression in youth with autism spectrum disorders (ASD), according to a systematic... (Source: Family Practice News)
Source: Family Practice News - March 2, 2016 Category: Primary Care Source Type: news

Understanding & Giving Support to Someone with Schizophrenia
What comes to mind when the word schizophrenia is spoken? Likely images of a bedraggled man or woman, with wild hair and tattered clothing, chatting away with someone that you can’t see, as they amble down a city street. You might actually cross the street to avoid him or her, so as not to get caught up in their delusion. The Diagnostic and Statistical Manual of Mental Disorders (DSM-V) describes the condition as “characterized by delusions, hallucinations, disorganized speech and behavior, and other symptoms that cause social or occupational dysfunction. For a diagnosis, symptoms must have been present for six...
Source: Psych Central - February 1, 2016 Category: Psychiatry Authors: Edie Weinstein, MSW, LSW Tags: Antipsychotics Atypical Antipsychotics Caregivers Disorders Family General Medications Psychology Psychotherapy Schizophrenia Treatment American Psychiatric Association Delusion Delusional disorder Diagnostic And Statistical Ma Source Type: news

Smart Pill Can Tell Doctor If Patient Is Taking Medication
BOSTON (CBS) – It may sound like science fiction or perhaps more like Big Brother — a medication that can tell your doctor whether you’ve swallowed it or not. Many patients take a drug called Abilify to treat schizophrenia, bipolar disorder or depression, but soon patients may be offered a high-tech version of Abilify, a “smart pill”. It looks like a regular pill but hidden inside is a sensor which when swallowed sends a signal to a patch on a patient’s arm that transmits a message to the patient’s mobile phone verifying that the medication was taken. The data can also be sent to t...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 22, 2015 Category: Consumer Health News Authors: deanreddington Tags: Health Local News Dr. Mallika Marshall smart pill Source Type: news

What It’s Like to Be Inpatient with Dissociative Identity Disorder: Part 2
Looking back on my/our times inpatient, I see an array of different experiences. While at first I felt locked up, caged and incapacitated, later on I felt safer and more in agency of myself. My first inpatient experience was in 2010. I was in a psychiatric hospital from April to June 2010. The rooms were cold, with white walls and loud air conditioning. I always fell asleep watching the wall, the shadows portrayed on it by the blinds. The worst of all was when the visits went from once a week to none. When my phone was taken away from me. When I wasn’t allowed to see my parents. Being caged in a room with no lock, no...
Source: Psych Central - December 17, 2015 Category: Psychiatry Authors: Lilu Tags: Caregivers Children and Teens Disorders Dissociation Dissociative General Medications Personal Stories Psychiatry Psychology Treatment Dissociative Disorder Hospital Involuntary Commitment Mental Disorder Psychiatric Hospital Source Type: news

Sovaldi is expensive, but this drug cost N.C. Medicaid even more
The Gilead Sciences (Nasdaq: GILD) Hepatitis C treatment Sovaldi has contributed to increasing Medicaid costs in recent years, but there was one drug that cost Medicaid even more. The drug that cost N.C. Medicaid more than any other in 2014 was the antipsychotic drug Abilify, a treatment for Major Depressive Disorder, Irritability Associated with Autistic Disorder and other indications, made by Otsuka America Pharmaceutical. In 2014, Ability cost N.C. Medicaid $85 million, according to a report… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 15, 2015 Category: Biotechnology Authors: Jason deBruyn Source Type: news

Abilify (aripiprazole) Digital Medicine for Treatment of Schizophrenia
Abilify (aripiprazole), an orally administered dopamine partial agonist and a seratonin antagonist, was approved by US Food and Drug Administration (FDA) in November 2002 for the treatment of schizophrenia. (Source: Drug Development Technology)
Source: Drug Development Technology - November 23, 2015 Category: Pharmaceuticals Source Type: news

Facts You Should Know if Taking Abilify for...
Read about the use of Abilify in bipolar disorder and other health conditions, as well as information on its side effects and two black box warnings. (Source: About.com Bipolar Disorder)
Source: About.com Bipolar Disorder - November 17, 2015 Category: Psychiatry Authors: bipolar.guide at about.com Tags: health Source Type: news

Kids' Aripiprazole Ingestion May Have Led to False-Positive Amphetamine Results (FREE)
By Kelly Young Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH Accidental ingestion of the atypical antipsychotic aripiprazole by two children was associated with false-positive results for amphetamine on urine drug screens, according to … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 2, 2015 Category: Primary Care Source Type: news

Safety of Vraylar vs. Other Antipsychotics Drugs Compared in New Drug...
Comparative safety research review covers Abilify (Bristol-Meyers), Fanapt (Novartis), INVEGA (J&J), Risperdal (J&J), Risperdal Consta (Janssen)(PRWeb October 26, 2015)Read the full story at http://www.prweb.com/releases/2015/10/prweb13042760.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 26, 2015 Category: Pharmaceuticals Source Type: news

Do We Need a New Pill Drill?
Commercials that get into our kids heads drive us crazy. When we see them salivating over enticing ads designed to make them pine for every last morsel of candy, new gimmick or any unhealthy vice, we are outraged. And we should be. It's pretty despicable companies do this. As adults, we are also of great interest to marketers, but the version of "candy" being shoved down our throats -- almost literally -- are prescription meds. The United States, along with New Zealand are the only two countries across the world that allows Direct-to-Consumer (DTC) pharmaceutical advertisements. We turn on our television and ar...
Source: Healthy Living - The Huffington Post - October 25, 2015 Category: Consumer Health News Source Type: news

Aristada™ (aripiprazole lauroxil) for the Treatment of Schizophrenia
Aristada™ (aripiprazole lauroxil), discovered and developed by Alkermes, is an antipsychotic drug indicated for the treatment of schizophrenia in adults. (Source: Drug Development Technology)
Source: Drug Development Technology - October 20, 2015 Category: Pharmaceuticals Source Type: news

Aristada (Aripiprazole Lauroxil Extended-release Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 14, 2015 Category: Drugs & Pharmacology Source Type: news

Extended-Release Schizophrenia Drug Approved (FREE)
By Kristin J. Kelley Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM The FDA has approved extended-release aripiprazole lauroxil (marketed as … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 7, 2015 Category: Primary Care Source Type: news

FDA Clears Long-Lasting Drug for Schizophrenia
The FDA has approved a version of the antipsychotic drug aripiprazole that adults with schizophrenia can take every 4-6 weeks. WebMD has the details. (Source: WebMD Health)
Source: WebMD Health - October 6, 2015 Category: Consumer Health News Source Type: news

FDA Approves Alkermes' Injectable Schizophrenia Drug
Alkermes' Aristada (aripiprazole lauroxil) extended release injection is approved to treat adults with schizophrenia (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 6, 2015 Category: Pharmaceuticals Source Type: news

FDA Clears Long-Acting Aripiprazole for SchizophreniaFDA Clears Long-Acting Aripiprazole for Schizophrenia
The FDA has approved an injectable, long-acting version of Alkermes Inc's atypical antipsychotic aripiprazole to treat adults with schizophrenia. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 6, 2015 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

FDA approves new injectable drug to treat schizophrenia
On October 5, the U.S. Food and Drug Administration approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Aristada is administered by a health care professional every four to six weeks using an injection in the arm or buttocks. (Source: Food and Drug Administration)
Source: Food and Drug Administration - October 6, 2015 Category: American Health Source Type: news

Alkermes' schizophrenia drug Aristada gets FDA nod
(Reuters) - The U.S. Food and Drug Administration on Monday approved Alkermes Plc's longer-acting injectable version of blockbuster schizophrenia pill Abilify, making the treatment available in two doses. (Source: Reuters: Health)
Source: Reuters: Health - October 6, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Alkermes's Aristada gets FDA approval to treat schizophrenia
Ireland-based Alkermes has received approval from the US Food and Drug Administration (FDA) for Aristada (aripiprazole lauroxil) extended-release injectable suspension to treat schizophrenia. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 6, 2015 Category: Pharmaceuticals Source Type: news

This Treatment May Help Depression in Older People
When a doctor prescribes aripiprazole (Abilify), an antipsychotic drug, for an older person already taking the antidepressant venlafaxine, that combination can help ease depression that doesn't get better with typical treatment, according to a new study. (Source: WebMD Health)
Source: WebMD Health - October 1, 2015 Category: Consumer Health News Source Type: news

Add-On Aripiprazole Helps Manage Treatment-Resistant Depression in Elders (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH Adding the atypical antipsychotic aripiprazole (Abilify) to an antidepressant can help older adults with difficult-to-treat depression, a Lancet study finds. Over … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 28, 2015 Category: Primary Care Source Type: news

FDA to review Proteus ‘smart pill’ with Otuka’s Abilify anti-depressant
Otsuka Pharmaceutical (TYO:4578) and Proteus Digital Health said yesterday that the FDA will review a combination of the Proteus “smart pill” and Otsuka’s Abilify anti-depressant drug. The companies said the FDA accepted their new drug application for the drug-device combination, using the Proteus ingestible sensor and Otsuka’s aripiprazole drug in patients with serious mental illnesses such as major depressive disorder, bipolar disorder and schizophrenia. It’s the 1st time the federal safety watchdog has reviewed a drug-device combo designed to measure adherence. The Proteus pi...
Source: Mass Device - September 11, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Drug-Device Combinations Otsuka Pharmaceutical Proteus Digital Health Source Type: news

Proteus, Otsuka submit first commercial drug with built-in sensor to FDA
After years of using its digital health feedback system in clinical trials and studies, Proteus Digital Health, and partner Otsuka Pharmaceuticals, are poised to launch the first mass market drug to incorporate Proteus’s ingestible sensor. The companies have submitted a sensor-embedded version of the antidepressant Abilify for FDA approval. “Today, patients suffering from severe mental […] (Source: mobihealthnews)
Source: mobihealthnews - September 10, 2015 Category: Information Technology Authors: Jonah Comstock Tags: Government/Regulation Pharma Uncategorized Abilify ingestible sensor Otsuka Pharmaceuticals Proteus Digital Health Proteus Digital Health feedback system Source Type: news

CHMP Backs Three Generics for Major Mental IllnessesCHMP Backs Three Generics for Major Mental Illnesses
The EMA committee gives green light to Duloxetine Zentiva, Aripiprazole Sandoz, and Pregabalin Accord. Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - June 26, 2015 Category: Psychiatry Tags: Psychiatry News Source Type: news

Otsuka loses lawsuit challenging FDA approval of generic Abilify
(Reuters) - Otsuka Pharmaceutical Co Ltd has lost a lawsuit challenging the U.S. Food and Drug Administration's decision to allow generic versions of the company's antipsychotic drug Abilify. (Source: Reuters: Health)
Source: Reuters: Health - May 28, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

NeuroBreak: Denial for Survival, Generic Abilify
(MedPage Today) -- News and commentary from the world of neurology and neuroscience. (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - May 5, 2015 Category: Neurology Source Type: news

Monthly News Roundup - April 2015
FDA Approves First-Time Generic for BMS’s Abilify Abilify (aripiprazole) is a blockbuster atypical antipsychotic drug used to treat the mental illnesses schizophrenia and bipolar disorder. On April 28th, the U.S. Food and Drug Administration... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 30, 2015 Category: Pharmaceuticals Source Type: news

FDA Approves First Generic Versions of Abilify (FREE)
By the Editors The FDA on Tuesday approved the first generic versions of the atypical antipsychotic Abilifiy (aripiprazole) for … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 30, 2015 Category: Primary Care Source Type: news

FDA grants approval for generic version of antipsychotic drug Abilify
The US Food and Drug Administration (FDA) has granted approval for the first generic versions of Abilify (aripiprazole), which is an atypical antipsychotic drug to treat schizophrenia and bipolar disorder. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 30, 2015 Category: Pharmaceuticals Source Type: news

FDA Okays First Aripiprazole GenericsFDA Okays First Aripiprazole Generics
The FDA has approved the first generic versions of the atypical antipsychotic aripiprazole. FDA Approvals (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - April 29, 2015 Category: Psychiatry Tags: Psychiatry News Alert Source Type: news

FDA Approves Generic Abilify: Teva, Alembic, Hetero, Torrent Come to Market
Generic aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 28, 2015 Category: Pharmaceuticals Source Type: news

FDA approves generic versions of antipsychotic drug Abilify
(Reuters) - The U.S. Food and Drug Administration said it approved the first copycat versions of Otsuka Pharmaceutical Co Ltd's antipsychotic drug, Abilify. (Source: Reuters: Health)
Source: Reuters: Health - April 28, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves first generic Abilify to treat mental illnesses
The U.S. Food and Drug Administration today approved the first generic versions of Abilify (aripiprazole). Generic aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder. (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 28, 2015 Category: American Health Source Type: news

FDA Approves First Generic Abilify (aripiprazole) to Treat Mental Illnesses
April 28, 2015 -- The U.S. Food and Drug Administration today approved the first generic versions of Abilify (aripiprazole). Generic aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder. Alembic... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 28, 2015 Category: Pharmaceuticals Source Type: news

aripiprazole, Abilify
Title: aripiprazole, AbilifyCategory: MedicationsCreated: 2/17/2004 12:00:00 AMLast Editorial Review: 4/13/2015 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - April 13, 2015 Category: Drugs & Pharmacology Source Type: news

FDA Okays Aripiprazole for Acute Schizophrenia RelapseFDA Okays Aripiprazole for Acute Schizophrenia Relapse
The FDA has approved a labeling update for the long-acting injectable antipsychotic aripiprazole. News Alerts (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - December 9, 2014 Category: Psychiatry Tags: Psychiatry News Alert Source Type: news